Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP992889priorityCriticalpatent/ECSP992889A/en
Publication of ECSP992889ApublicationCriticalpatent/ECSP992889A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente invención se refiere a métodos y dispositivos para administrar una formulación de un agente activo a los pulmones de un paciente humano. La formulación del agente activo puede presentarse en forma de polvo seco, o puede ser nebulizado, o puede estar mezclado con un impelente. La formulación del agente activo se administra a un paciente a un indice de flujo inspiratorio inferior a 17 litros por minuto. Se observó que la biodisponibilidad del agente activo aumenta a estos indices de flujo en comparación con indices de flujo inspiratorio de 17 litros por minuto o más.The present invention relates to methods and devices for administering a formulation of an active agent to the lungs of a human patient. The active agent formulation may be in the form of a dry powder, or it may be nebulized, or it may be mixed with an impeller. The active agent formulation is administered to a patient at an inspiratory flow rate of less than 17 liters per minute. The bioavailability of the active agent was observed to increase at these flow rates compared to inspiratory flow rates of 17 liters per minute or more.
ECSP9928891999-03-161999-03-16
ADMINISTRATION OF AN ACTIVE AGENT IN AEROSOL
ECSP992889A
(en)
Intranasal sufentanil/midazolam versus ketamine/midazolam for analgesia/sedation in the pediatric population prior to undergoing multiple dental extractions under general anesthesia: a prospective, double-blind, randomized comparison.
Use of 5- (2-pyrazinyl) -4-methyl-1-2-dithiol-3-thione (oltipraz) as a medicine, pharmaceutical composition for the prevention and treatment of hepatic fibrosis progression, use of 5- (2- pyrazinyl) -4-methyl-1,2-dithiol-3-thione and method for the prevention and treatment of fibrosis progression and liver cirrhosis